Aprogen Biologics amends KRW 20 billion share sale to fund loan to Einspack

Bitget2026/09/23 06:23

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aprogen Biologics issued a correction to its Sept. 3 paid-in capital increase filing, reclassifying the funding purpose to “other funds.”
The KRW 20 billion third-party allotment will fund strategic lending to EinsPack to support financial structure improvements.
Shares to be issued remain 12,706,481 common shares at KRW 1,574 each, a 10% discount to a KRW 1,748 reference price.
The allottee remains controlling shareholder Aprogen, subject to a one-year lock-up from the listing date.
Payment date is Sept. 23, 2026; listing is scheduled for Oct. 13, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprogen Biologics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260923000418), on September 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aprogen Biologics amends KRW 20 billion share sale to fund loan to Einspack

You may also like

Crypto prices